The influence of matriptase-2 on prostate cancer in vitro: A possible role for β-catenin

Webb,Siobhan  L.; Sanders,Andrew  J.; Mason,Malcolm  D.; Jiang,Wen  G.

doi:10.3892/or.2012.1945

The influence of matriptase-2 on prostate cancer in vitro: A possible role for β-catenin

Authors:
- Siobhan L. Webb
- Andrew J. Sanders
- Malcolm D. Mason
- Wen G. Jiang
View Affiliations

Affiliations: Metastasis and Angiogenesis Research Group, Institute of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK
Published online on: August 2, 2012 https://doi.org/10.3892/or.2012.1945
Pages: 1491-1497

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The type II transmembrane serine proteases (TTSPs) are a family of cell surface proteolytic enzymes contributing to a number of processes, such as tumour invasion and metastasis. Within the TTSPs, matriptase-2 is a relatively newly identified member and this protease has been shown to play a key role in cancer progression. β-catenin has long been regarded as an oncogene. The deregulation of the β-catenin signalling pathway plays a significant role in the progression and possibly the development of cancer. However, little is known about the role of matriptase-2 in prostate cancer. This study aimed to examine the correlation between matriptase-2 and β-catenin. Matriptase-2 was knocked down in the normal prostate cells, PZHPV7 and PNT2C2, using a ribozyme transgene targeting matriptase-2. The altered cells were used in a number of in vitro experiments designed to investigate the involvement of matriptase-2 with β-catenin and to further characterise its function. The knockdown of matriptase-2 had no effect on cell growth or adhesion but significantly reduced cell motility (PZHPV7 cells, p<0.001; PNT2C2 cells, p=0.001 vs. respective control cells) and invasive capability (PZHPV7 cells, p=0.001; PNT2C2 cells, p=0.007). The knockdown also caused a large increase in β-catenin protein expression at the cell membrane in PZHPV7 and PNT2C2 cells and a decrease in PC3 cells overexpressing matriptase-2, but did not affect the mRNA levels. Matriptase-2 may have an important impact on prostate cancer progression. The data gained from this study suggest that matriptase-2 protects against the development and progression of prostate cancer by regulating the motility and invasive capabilities of prostate cancer cells. Matriptase-2 also reduces the levels of β-catenin at the cell membrane. As β-catenin is highly involved in the regulation of cellular processes, including motility and invasion, the reduction of β-catenin expression by matriptase-2 may be a possible mechanism by which matriptase-2 functions.

View Figures

View References

1	Lang JC and Schuller DE: Differential expression of a novel serine protease homologue in squamous cell carcinoma of the head and neck. Br J Cancer. 84:237–243. 2001. View Article : Google Scholar : PubMed/NCBI
2	Lee JW, Yong Song S, Choi JJ, et al: Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Hum Pathol. 36:626–633. 2005. View Article : Google Scholar : PubMed/NCBI
3	Magee JA, Araki T, Patil S, et al: Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 61:5692–5696. 2001.PubMed/NCBI
4	Netzel-Arnett S, Hooper JD, Szabo R, et al: Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev. 22:237–258. 2003. View Article : Google Scholar : PubMed/NCBI
5	Wallrapp C, Hahnel S, Muller-Pillasch F, et al: A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer. Cancer Res. 60:2602–2606. 2000.PubMed/NCBI
6	Velasco G, Cal S, Quesada V, Sanchez LM and Lopez-Otin C: Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins. J Biol Chem. 277:37637–37646. 2002. View Article : Google Scholar
7	Hooper JD, Campagnolo L, Goodarzi G, Truong TN, Stuhlmann H and Quigley JP: Mouse matriptase-2: identification, characterization and comparative mRNA expression analysis with mouse hepsin in adult and embryonic tissues. Biochem J. 373:689–702. 2003. View Article : Google Scholar
8	Szabo R and Bugge TH: Type II transmembrane serine proteases in development and disease. Int J Biochem Cell Biol. 40:1297–1316. 2008. View Article : Google Scholar : PubMed/NCBI
9	Shi YE, Torri J, Yieh L, Wellstein A, Lippman ME and Dickson RB: Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res. 53:1409–1415. 1993.PubMed/NCBI
10	Tsai WC, Chu CH, Yu CP, et al: Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters. Dis Markers. 24:89–99. 2008. View Article : Google Scholar
11	Uhland K: Matriptase and its putative role in cancer. Cell Mol Life Sci. 63:2968–2978. 2006. View Article : Google Scholar : PubMed/NCBI
12	Parr C, Sanders AJ, Davies G, et al: Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients. Clin Cancer Res. 13:3568–3576. 2007. View Article : Google Scholar : PubMed/NCBI
13	Sanders AJ, Parr C, Martin TA, Lane J, Mason MD and Jiang WG: Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation. J Cell Physiol. 216:780–789. 2008. View Article : Google Scholar : PubMed/NCBI
14	Hart M, Concordet JP, Lassot I, et al: The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol. 9:207–210. 1999. View Article : Google Scholar : PubMed/NCBI
15	He TC, Sparks AB, Rago C, et al: Identification of c-MYC as a target of the APC pathway. Science. 281:1509–1512. 1998. View Article : Google Scholar : PubMed/NCBI
16	Brabletz T, Jung A, Dag S, Hlubek F and Kirchner T: beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol. 155:1033–1038. 1999. View Article : Google Scholar : PubMed/NCBI
17	Crawford HC, Fingleton BM, Rudolph-Owen LA, et al: The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene. 18:2883–2891. 1999. View Article : Google Scholar : PubMed/NCBI
18	Zhang X, Gaspard JP and Chung DC: Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res. 61:6050–6054. 2001.PubMed/NCBI
19	Boon EM, van der Neut R, van de Wetering M, Clevers H and Pals ST: Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res. 62:5126–5128. 2002.PubMed/NCBI
20	Chesire DR, Ewing CM, Sauvageot J, Bova GS and Isaacs WB: Detection and analysis of beta-catenin mutations in prostate cancer. Prostate. 45:323–334. 2000. View Article : Google Scholar : PubMed/NCBI
21	Gerstein AV, Almeida TA, Zhao G, et al: APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer. 34:9–16. 2002. View Article : Google Scholar : PubMed/NCBI
22	Voeller HJ, Truica CI and Gelmann EP: Beta-catenin mutations in human prostate cancer. Cancer Res. 58:2520–2523. 1998.PubMed/NCBI
23	Chesire DR, Ewing CM, Gage WR and Isaacs WB: In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene. 21:2679–2694. 2002. View Article : Google Scholar
24	de la Taille A, Rubin MA, Chen MW, et al: Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res. 9:1801–1807. 2003.PubMed/NCBI
25	Gounari F, Signoretti S, Bronson R, et al: Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene. 21:4099–4107. 2002. View Article : Google Scholar
26	Bierie B, Nozawa M, Renou JP, et al: Activation of beta-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene. 22:3875–3887. 2003. View Article : Google Scholar : PubMed/NCBI